Related Experiment Videos
[Anemia and lung cancer].
1Service d'Oncologie Médicale, Hôpital Avicenne, Université Paris-XIII, AP-HP, 125 Route de Stalingrad, 93009 Bobigny Cedex, France. jeanne-marie.brechot@avc.ap-hop-paris.fr
Revue De Pneumologie Clinique
|July 1, 2008
Summary
Erythropoietin (EPO) effectively manages cancer anemia, improving chemotherapy tolerance and patient quality of life. Updated guidelines address concerns regarding EPO
Area of Science:
- Oncology
- Hematology
- Pharmacology
Context:
- Anemia is prevalent in lung cancer patients, impacting treatment tolerance.
- Erythropoietin (EPO) is a key therapeutic agent for cancer-related anemia.
- Existing guidelines for EPO use in cancer patients require updates.
Purpose:
- To present updated guidelines for Erythropoietin (EPO) treatment in lung cancer patients.
- To address the ongoing debate regarding the safety of EPO in neoplastic diseases.
- To consider the role of EPO receptors in tumor biology, including non-small cell lung cancer.
Summary:
- Erythropoietin (EPO) treatment significantly enhances chemotherapy tolerance and quality of life for cancer patients.
- High prevalence and incidence of anemia are noted in lung cancer populations.
- Updated guidelines incorporate discussions on potential adverse effects of EPO on cancer progression and tumor EPO receptor expression.
Impact:
- Improved patient outcomes through better anemia management during cancer therapy.
- Informed clinical decision-making regarding EPO use in lung cancer.
- Further research into the interaction between EPO, its receptors, and tumor growth.
Related Concept Videos
01:17Other Pulmonary Disorders
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:10Atelectasis II: Pathophysiology
Atelectasis develops when alveoli lose their air and collapse inward. Because lung tissue is naturally elastic, these air sacs shrink rather than remaining open. Collapsed alveoli are no longer ventilated, reducing their role in gas exchange. Blood flow may continue in these regions, creating a ventilation–perfusion mismatch. Clinical findings include decreased breath sounds, dullness to percussion, reduced chest expansion, and decreased tactile fremitus as sound transmission through collapsed...
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...